VCM
TEVA icon

Virtue Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Virtue Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,121
Closed -$20K – 435
2018
Q1 		$20K Buy
1,121
+24
+2% +$469 0.01% 325
2017
Q4 		$21K Buy
+1,097
New +$16.5K 0.01% 284

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Virtue Capital Management's TEVA Position: Q2 2018 in Review

Virtue Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 1,121 shares — an estimated $20K sold.

Virtue Capital Management first reported a position in TEVA in Q4 2017 and held it in 2 quarters. The position peaked at $21K in Q4 2017. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

  • Virtue Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Virtue Capital Management sold 1,121 Teva Pharmaceuticals shares in Q2 2018, an estimated $20K.
  • Virtue Capital Management first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Virtue Capital Management's Teva Pharmaceuticals position peaked at $21K in Q4 2017.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Virtue Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.